Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - sertindol - filmovertrukne tabletter - 12 mg

Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - sertindol - filmovertrukne tabletter - 16 mg

Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - oxytocin - injektionsvæske, opløsning - 10 ie/ml

Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - aciclovir - øjensalve - 3 %

Dania - duński - SEGES Landbrug & Fødevarer

adama northern europe b.v. - florasulam, fluroxypyr - suspoemulsion - 2,5 g/l florasulam ; 100 g/l fluroxypyr

Dania - duński - SEGES Landbrug & Fødevarer

adama northern europe b.v. - metamitron - suspensionskoncentrat - 700 g/l metamitron

Dania - duński - SEGES Landbrug & Fødevarer

bayer a/s - penflufen - flydende bejdse - 50 g/l penflufen

Dania - duński - SEGES Landbrug & Fødevarer

syngenta nordics a/s - fludioxonil, thiamethoxam, metalaxyl-m - flydende bejdse - 8 g/l fludioxonil ; 280 g/l thiamethoxam ; 33,3 g/l metalaxyl-m

Dania - duński - SEGES Landbrug & Fødevarer

syngenta nordics a/s - difenoconazol, fludioxonil, sedaxan - flydende bejdse - 25 g/l difenoconazol; 25 g/l fludioxonil; 50 g/l sedaxane

Unia Europejska - duński - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.